Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, has reached an agreement with South Korean company PRG S&T to obtain a license for Progerinin (SLC-D011), an investigational drug for the treatment of Hutchinson-Gilford Progeria Syndrome. Under the agreement, Sentynl will acquire full rights to the FDA-designated orphan drug upon achieving specific milestones, adding a second potential early aging therapy to its rare disease product portfolio. The oral small molecule candidate drug targets harmful progeria protein and is currently undergoing Phase IIA clinical trials, with data expected to be obtained by mid-2026.